Glioblastoma, IDH-wildtype Clinical Trials

30 recruitingLast updated: June 18, 2026

There are 30 actively recruiting glioblastoma, idh-wildtype clinical trials across 14 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Leuven, Belgium, Rotterdam, South Holland, Netherlands, Bern, Switzerland. Updated daily from ClinicalTrials.gov.


Glioblastoma, IDH-wildtype Trials at a Glance

30 actively recruiting trials for glioblastoma, idh-wildtype are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Leuven, Rotterdam, and Bern. Lead sponsors running glioblastoma, idh-wildtype studies include Jasper Gerritsen, Mayo Clinic, and National Cancer Institute (NCI).

Browse glioblastoma, idh-wildtype trials by phase

Treatments under study

About Glioblastoma, IDH-wildtype Clinical Trials

Looking for clinical trials for Glioblastoma, IDH-wildtype? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma, IDH-wildtype trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma, IDH-wildtype clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 1

A Study of 177Lu-PSMA-617 in People With Gliomas

GliomaGlioblastoma, IDH-wildtypeDiffuse Midline Glioma, H3 K27-Altered+3 more
Memorial Sloan Kettering Cancer Center20 enrolled7 locationsNCT07223034
Recruiting
Phase 3

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Brain CancerGlioblastomaGBM+4 more
Northwell Health432 enrolled1 locationNCT05271240
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 2

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Glioblastoma, IDH-wildtype
ECOG-ACRIN Cancer Research Group100 enrolled12 locationsNCT06319027
Recruiting
Not Applicable

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Glioblastoma, IDH-wildtypeWHO Grade 4 Glioma
Mayo Clinic116 enrolled3 locationsNCT07091864
Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 3

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Glioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma
Vastra Gotaland Region200 enrolled20 locationsNCT06419946
Recruiting
Phase 2

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Glioblastoma, IDH-wildtypeRecurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype+6 more
Mayo Clinic36 enrolled1 locationNCT07301268
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1Phase 2

A Clinical Trial of P134 Cells in Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
Tasly Pharmaceutical Group Co., Ltd26 enrolled1 locationNCT07318818
Recruiting
Phase 2

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent GliosarcomaHigh Grade Astrocytic Tumor
Mayo Clinic54 enrolled1 locationNCT05465954
Recruiting
Phase 2

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma, IDH-wildtypeMGMT-Unmethylated Glioblastoma
Northwestern University39 enrolled2 locationsNCT05879250
Recruiting
Phase 2

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

Glioblastoma, IDH-wildtype
Hopital Foch640 enrolled7 locationsNCT04945148
Recruiting
Phase 1

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Recurrent Glioblastoma, IDH-Wildtype
Darell Bigner46 enrolled1 locationNCT06455605
Recruiting
Phase 2

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Glioblastoma, IDH-wildtypeMetforminMalignancies
University of Milano Bicocca25 enrolled1 locationNCT05929495
Recruiting
Phase 1

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

GlioblastomaGBMGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc.66 enrolled8 locationsNCT05879367